

This form is based on Express Scripts standard criteria and may not be applicable to all patients; certain plans and situations may require additional information beyond what is specifically requested.

Additional forms available: www.express-scripts.com/pa

Fax completed form to **1-877-329-3760**If this an **URGENT** request, please call 1-800-753-2851

Patient Information	Prescribe	r Informatio	on
Patient First Name:	Prescriber Name:		
Patient Last Name:	Prescriber DEA/NPI (required):		
	Prescriber Phone #:		
Patient ID#:	Prescriber Fax #:		
Patient DOB:	Prescriber Address:		
Patient Phone #:	State: Zip Code:		
Primary Diagnosis:	ICD Code:		
☐ Celebrex 50mg ☐ Celebrex 100mg Directions for use (i.e. QD, BID, PRN & Qty): Please complete the clinical assessment:	□ Celebrex 200mg	□ Celebrex 40	
Is the patient currently taking the requested medication?		☐ Yes	□ No
 2. Is the patient taking samples or paying 100% out of pocken of pocken lf no, please indicate: Requested medication covered under previous insurples of started medication in hospital Other: 	rance plan	☐ Yes	□ No
3. Has the patient tried 2 oral prescription-strength NSAIDs (current condition?	may be brand or generic) for the	☐ Yes	□ No
4. Please list the oral prescription-strength NSAIDs (may be be include the strength and directions for use:		or the current cond	lition. Please
	the state of the s		
5. Is the patient currently receiving chronic systemic corticos warfarin (Coumadin), clopidogrel (Plavix), dabigatran (Prarivaroxaban (Xarelto), Effient (prasugrel), chronic aspirin theparin (e.g., fondaparinux (Arixtra), tinzaparin (Innohep) (Fragmin))?	daxa), ticagrelor (Brilinta), herapy, or low-molecular weight	☐ Yes	□ No
6. Is Celebrex being used to treat a chronic condition?		☐ Yes	□ No

Celebrex F14 9.4.2013

7. Does the patient have reduced platelet counts or other coagulation disorders?	□ Yes	□ No
8. Does the patient have familial adenomatous polyposis (FAP) or attenuated adenomatous polyposis coli (AAPC)?	☐ Yes	□ No
9. Has the patient had a documented upper GI bleed from a duodenal or gastric ulcer?	☐ Yes	□ No
10. Does the patient have aspirin-sensitive asthma (also known as aspirin-induced asthma, aspirin-exacerbated respiratory disease) or NSAID-induced asthma?	☐ Yes	□ No
11. Has the patient experienced a past hypersensitivity, anaphylactic or allergic-type reaction (e.g., erythema, hives, urticaria, angioedema) to aspirin or NSAIDs? If so, what was the reaction?	☐ Yes	□ No

Are there any other comments, diagnoses, symptoms, and/or any other information the physician feels is important to this review?

Prescriber Signature: _	Date:
Office Contact Name: _	Phone Number:

Based upon each patient's prescription plan, additional questions may be required to complete the prior authorization process. If you have any questions about the process or required information, please contact our prior authorization team at the number listed on the top of this form.

Prior Authorization of Benefits is not the practice of medicine or a substitute for the independent medical judgment of a treating physician. Only a treating physician can determine what medications are appropriate for the patient. Please refer to the applicable plan for the detailed information regarding benefits, conditions, limitations, and exclusions.

The document(s) accompanying this transmission may contain confidential health information. This information is intended only for the use of the individual or entity named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you received this information in error, please notify the sender immediately and arrange for the return or destruction of the documents.

Celebrex F14 9.4.2013